Blumenfeld A, Schim J, Chippendale T. Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine. Headache: The Journal of Head and Face Pain. 2007;48(2):210-220. doi:10.1111/j.1526-4610.2007.00949.x. This journal article summarizes the results of a randomized, double blind, prospective study that focused on comparing the safety and efficacy of botulinum toxin type A and Divalproex Sodium. These two drugs, botulinum toxin type A (botox) and Divalproex Sodium (an anticonvulsant drug) are used as prophylactic measures for migraines. This article is significant because tolerability is validated at the conclusion of the study.
Cady R. Chronic migraine in women. The Journal of Family Practice. …show more content…
The final results were analyzed along with the Physician Global Assessment at the 12 week mark and proved to be significant in efficacy for both groups.
Diener H, Dodick D, Turkel C et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851-859. doi:10.1111/ene.12393. This journal article discusses the efficacy, safety and tolerability of botox injections during a randomized, double blinded, placebo controlled study during phase 3 of clinical trials. Studies show that five treatment cycles of this injection are proven to be effective when used as a preventative measure for patients that suffer from chronic migraine.
Grazzi L, Usai S. Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse. Neurological Sciences. 2014;35(S1):37-39. …show more content…
The results are significant because at the end of the study the injections were proven to be clinically applicable for the majority of patient cases with chronic migraine.
Irimia P, Carmona-Abellán M, MartÃnez-Vila E. Chronic migraine: a therapeutic challenge for clinicians. Expert Opin Emerging Drugs. 2012;17(4):445-447. doi:10.1517/14728214.2012.726612. This research article analyzes the few known methods for migraine prophylaxis and rules out the efficacy of original form of treatment. As research continues to be conducted, clinicians and other health care providers will understand the pathophysiology of migraines which will eventually contribute to the discovery of new treatment targets. This source is significant because we are provided with current strategies on migraine prophylaxis and treatment which are then analyzed and compared in regards to their efficacy, compliance level and popularity.
Lipton R, Varon S, Grosberg B et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011;77(15):1465-1472.